Jaguar Animal Health (JAGX) Expected to Post Quarterly Earnings on Thursday

Jaguar Animal Health (NASDAQ:JAGX) is expected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Jaguar Animal Health to post earnings of ($52.15) per share and revenue of $4.24 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 28, 2026 at 9:30 AM ET.

Jaguar Animal Health (NASDAQ:JAGX) last announced its quarterly earnings results on Wednesday, May 20th. The biotechnology company reported ($13.60) EPS for the quarter, beating analysts’ consensus estimates of ($149.10) by $135.50. The business had revenue of $20.27 million for the quarter, compared to the consensus estimate of $4.21 million.

Jaguar Animal Health Trading Down 6.1%

JAGX opened at $0.78 on Wednesday. Jaguar Animal Health has a 1-year low of $0.77 and a 1-year high of $92.75. The company has a market cap of $472,390.20, a price-to-earnings ratio of -0.00 and a beta of -0.06. The company’s fifty day moving average price is $2.03 and its two-hundred day moving average price is $10.37.

Analyst Upgrades and Downgrades

JAGX has been the subject of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Friday, July 17th. Wall Street Zen raised shares of Jaguar Animal Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.